Supplementary data: Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer

Supplementary Fig 1.

Overall cohort: Kaplan-Meier recurrence-free survival.

Supplementary Fig. 2.

Kaplan-Meier local recurrence-free survival analysis by chemotherapy regimen.

Supplementary Fig. 3.

Kaplan-Meier local recurrence-free survival analysis by chemoradiotherapy regimen.

Supplementary Table 1.

Delayed hematuria

Grade
1	4
2	0
3	4
4	5
5	0
Total	13
Total Grade 3–5	9
Hematuria
Associated with local recurrence	11/13 (84.6%)
Independent of local recurrence	2/13 (15.4%)

Supplementary Table 2.

Subgroup analysis: Complete response based on therapy

Radiation			Data unavailable
Complete response		p (Fisher exact test*)	Local recurrence
37.5–40 Gy	8/12 (66.7%)	0.3839	1/5
50–65 Gy	16/19 (84.2%)		3/4
Chemotherapy			Data unavailable
Complete response			Local recurrence
Carboplatin	14/21 (66.7%)	0.0661	4/9
Non-carbo	10/10 (100%)		0
Complete TUR
Complete response			Data unavailable
Incomplete	12/16 (75.0%)		5
Complete	10/13 (76.9%)	1.0000	3
Unspecified	1/2 (50.0%)		1

^*Fisher exact test analysis omits the data where information not documented. TUR: transurethral resection.

Supplementary Table 3.

Toxicities by chemotherapy regimen

Toxicity	Proportion of patients affected	p (FET)
Grade 1–2 toxicities
Carboplatin	18/30 (60.0%)	0.1238
Non-carbo	9/10 (90.0%)
Grade 3–5 toxicities
Carboplatin	5/30 (16.7%)	0.3059
Non-carbo	0/10 (0.0%)

FET: Fisher exact test.